Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The race for a Covid-19 vaccine or treatment is on.
With around 400 potential candidates in development, according to BioCentury, pharma companies have recognised their role in resolving the crisis.
They have applied themselves to the challenge without hesitation. However, the situation is bringing some difficult questions to the fore, not least the balancing act between public health and private interests.
The pharma industry, as a rule, tends to be fiercely protective of its intellectual property (IP) and indeed sees patents as key to innovation. “Intellectual property has not been an impediment to the common goal of ending.